DEALS
Zhong Lun Law Firm Advised Everest Medicines on its Series C Financing of US$310 Million
Zhong Lun Law Firm Advised Everest Medicines on its Series C Financing of US$310 Million
Release time：2020-06-05
Voice Announcements
On June 5, 2020, Everest Medicines announced that it has successfully completed US$310 million in Series C financing. Everest Medicines is a biopharmaceutical company focusing on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets.
The US$310 million Series C financing includes two preferred equity financing tranches, a US$260 million Series C-2 and a US$50 million Series C-1. The Series C-2 was led by Janchor Partners and co-led by RA Capital Management and Hillhouse Capital with additional support from new investors, including Decheng Capital, GT Fund, Janus Henderson Investors, Rock Springs Capital, Octagon Investments and a large, reputable long-term investor. Existing investors, including CBC Group, Cormorant, Pavilion Capital and HBM Healthcare Investments also participated. The Series C-1 comprised of a US$50 million investment from the Jiashan SDIC, which was part of a broader strategic partnership with Jiashan National Economic and Technological Development Zone and Jiashan SDIC announced on March 17, 2020.
As the long-term legal counsel of Everest Medicines since its establishment, Zhong Lun Law Firm provided full scope legal services for its Series C Financing, including but not limited to negotiation, drafting and revising legal documentation, assisting on the execution and the closing. Catherine Chen and Shaun Gao are the leading partners of this project. Team members also include Yun Hu.
Professionals
-
-
Catherine F. CHEN
Equity Partner
ShanghaiPractices： Private Equity & Investment Funds,Hong Kong & Overseas Capital Markets,Chinese Mainland Capital MarketsIndustries： Real Estate,Transportation & Logistics,Tourism & Hospitality,Insurance,Telecommunications & Internet,Information & Intelligence Technology,Pharmaceuticals & Life Sciences -
Catherine F. CHEN
Equity Partner
Shanghai
-
